|
Axial spondyloarthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Three LPPs [H-ficolin (ficolin-3), L-ficolin (ficolin-2) and collectin liver 1 (CL-L1)] were significantly higher in axSpA patients than in controls (P < 0·0001) and one LPP, collectin kidney 1 (CL-K1), was significantly lower (P < 0·0001).
|
31518441 |
2020 |
|
Acute Undifferentiated Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
|
31055076 |
2019 |
|
Undifferentiated leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
|
31055076 |
2019 |
|
Trisomy 12
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
By correlating these results to the presence of prognostic factors determined by fluorescence in situ hybridization, we found that the majority of the cases of group CLL1 (14/17) carried trisomy 12.
|
26119874 |
2017 |
|
Monoclonal B-Cell Lymphocytosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We performed deep next generation sequencing of the NOTCH1 mutation hotspot in 384 cases at diagnosis, including 100 monoclonal B cell lymphocytosis (MBL) and 284 Binet stage A CLL cases, enrolled in the Gruppo Italiano Studio Linfomi O-CLL1 multicentre trial.
|
24579978 |
2014 |
|
Waldenstrom Macroglobulinemia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P < 1.5 × 10(-5) for WM vs other cohorts).
|
23321251 |
2013 |
|
Monoclonal Gammopathy of Undetermined Significance
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P < 1.5 × 10(-5) for WM vs other cohorts).
|
23321251 |
2013 |
|
Multiple Myeloma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Using either assay, MYD88 L265P was detected in 97 of 104 (93%) WM and 13 of 24 (54%) IgM MGUS patients and was either absent or rarely expressed in samples from splenic marginal zone lymphoma (2/20; 10%), CLL (1/26; 4%), multiple myeloma (including IgM cases, 0/14), and immunoglobulin G MGUS (0/9) patients as well as healthy donors (0/40; P < 1.5 × 10(-5) for WM vs other cohorts).
|
23321251 |
2013 |
|
Acute lymphocytic leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CLL-1 showed variable expression (10-60%) in CD34(+) cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia.
|
15548716 |
2004 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CLL-1 showed variable expression (10-60%) in CD34(+) cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia.
|
15548716 |
2004 |
|
Childhood Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CLL-1 showed variable expression (10-60%) in CD34(+) cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia.
|
15548716 |
2004 |
|
MYELODYSPLASTIC SYNDROME
|
0.010 |
AlteredExpression
|
group |
BEFREE |
CLL-1 showed variable expression (10-60%) in CD34(+) cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia.
|
15548716 |
2004 |
|
Adult Myelodysplastic Syndrome
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
CLL-1 showed variable expression (10-60%) in CD34(+) cells in chronic myelogenous leukemia and myelodysplastic syndrome but was absent in 12 of 13 cases of acute lymphoblastic leukemia.
|
15548716 |
2004 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
|
9192768 |
1997 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Comparison of predictive value of prognostic scores for TTFT illustrated better performance of CLL-IPI (C = 0.72, AIC = 726) followed by Barcelona-Brno (C = 0.68, AIC = 743), modified GCLLSG (C = 0.66, AIC = 744), and O-CLL1 index (C = 0.55, AIC = 773).
|
30338367 |
2019 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
CLL1-ADC inhibits in vitro LSC colony formation and demonstrates robust in vivo efficacy in AML cell tumor models and tumor growth inhibition in the AML patient-derived xenograft model.
|
30037800 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
In this study we performed an investigation of the role of IGF1R expression in a large and representative prospective series of 217 chronic lymphocytic leukaemia (CLL) patients enrolled in the multicentre O-CLL1 protocol (clinicaltrial.gov #NCT00917540).
|
25786252 |
2015 |
|
Chronic Lymphocytic Leukemia
|
0.030 |
Biomarker
|
disease |
BEFREE |
Furthermore, the developed sensor was employed for profiling of three endogenous miRNAs characteristic to CLL, including hsa-miR-16-5p, hsa-miR-21-5p, and hsa-miR-150-5p in normal healthy serum, chronic lymphocytic leukemia Rai stage 1 (CLL-1), and stage 3 (CLL-3) sera, using a non-human cel-miR-39-3p as an internal standard.
|
25495265 |
2015 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
|
9192768 |
1997 |
|
Neoplasms
|
0.030 |
Biomarker
|
group |
BEFREE |
In contrast, EBV-CLL(1) could produce progressive tumors only in irradiated nude mice.
|
2841846 |
1988 |
|
Basal cell carcinoma
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Combined analysis of keratinocyte cancers identifies novel genome-wide loci.
|
31174203 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found GPR56 and CLL-1 to be the most prominently differently expressed surface markers in AML subcompartments.
|
30848055 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrate that CLL-1 shares similar prevalence and trafficking properties that make CD33 an excellent ADC target for AML, but lacks expression on hematopoietic stem cells that hampers current CD33-targeted ADCs.
|
29959143 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Daunorubicin-containing CLL1-targeting nanomicelles have anti-leukemia stem cell activity in acute myeloid leukemia.
|
31055076 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this paper, we will review the expression of CLL-1 on normal cells and AML, the value of CLL-1 in diagnosis and follow-up, and targeting CLL-1 therapy-based antibody and chimeric antigen receptor T cell therapy as well as providing an overview of CLL-1 as a target for AML.
|
31014360 |
2019 |